CCM
SBFM

Connective Capital Management’s Sunshine Biopharma SBFM Stock Holding History

Connective Capital Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,135
Closed -$34K – 79
2024
Q4 		$34K Buy
+1,135
New +$32.3K 0.04% 55

Other funds holding SBFM

ACM
Altium Capital Management New York $42M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

Connective Capital Management's SBFM Position: Q1 2025 in Review

Connective Capital Management sold out of Sunshine Biopharma (SBFM) in Q1 2025, closing a stake of 1,135 shares — an estimated $34K sold.

Connective Capital Management first reported a position in SBFM in Q4 2024 and held it in 1 quarter. The position peaked at $34K in Q4 2024. 6 funds tracked by Wall St. Rank hold SBFM as of Q1 2025.

  • Connective Capital Management reported no remaining Sunshine Biopharma position as of Q1 2025 after selling out during the quarter.
  • Connective Capital Management sold 1,135 Sunshine Biopharma shares in Q1 2025, an estimated $34K.
  • Connective Capital Management first reported a position in Sunshine Biopharma in Q4 2024 and held it in 1 quarter.
  • Connective Capital Management's Sunshine Biopharma position peaked at $34K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q1 2025.

Based on Connective Capital Management's 13F filing for Q1 2025, filed 14 May 2025.